Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Exploring Structure-Activity Relationships in Photodynamic Therapy Anticancer Agents Based on Ir(III)-COUPY Conjugates

dc.contributor.authorRovira, Anna
dc.contributor.authorOrtega Forte, Enrique
dc.contributor.authorHally, Cormac
dc.contributor.authorJordà-Redondo, Mireia
dc.contributor.authorAbad-Montero, Diego
dc.contributor.authorVigueras, Gloria
dc.contributor.authorMartínez, Jesús I.
dc.contributor.authorBosch Marimon, Manel
dc.contributor.authorNonell, Santi
dc.contributor.authorRuiz, José
dc.contributor.authorMarchán Sancho, Vicente
dc.date.accessioned2023-09-08T15:51:44Z
dc.date.available2023-09-08T15:51:44Z
dc.date.issued2023-06-02
dc.date.updated2023-09-08T15:51:44Z
dc.description.abstractPhotodynamic therapy holds great promise as a non-invasive anticancer tool against drug-resistant cancers. However, highly effective, non-toxic, and reliable photosensitizers with operability under hypoxic conditions remain to be developed. Herein, we took the advantageous properties of COUPY fluorophores and cyclometalated Ir(III) complexes to develop novel PDT agents based on Ir(III)-COUPY conjugates with the aim of exploring structure-activity relationships. The structural modifications carried out within the coumarin scaffold had a strong impact on the photophysical properties and cellular uptake of the conjugates. All Ir(III)-COUPY conjugates exhibited high phototoxicity under green light irradiation, which was attributed to the photogeneration of ROS, while remaining non-toxic in the dark. Among them, two hit conjugates showed excellent phototherapeutic indexes in cisplatin-resistant A2780cis cancer cells, both in normoxia and in hypoxia, suggesting that photoactive therapy approaches based on the conjugation of far-red/NIR-emitting COUPY dyes and transition metal complexes could effectively tackle in vitro acquired resistance to cisplatin.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec738222
dc.identifier.issn0022-2623
dc.identifier.urihttps://hdl.handle.net/2445/201842
dc.language.isoeng
dc.publisherAmerican Chemical Society
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1021/acs.jmedchem.3c00189
dc.relation.ispartofJournal of Medicinal Chemistry, 2023, vol. 66, num. 12, p. 7849-7867
dc.relation.urihttps://doi.org/10.1021/acs.jmedchem.3c00189
dc.rightscc-by (c) Rovira, Anna , 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)
dc.subject.classificationCompostos aromàtics
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationCumarines
dc.subject.otherAromatic compounds
dc.subject.otherCancer cells
dc.subject.otherCoumarins
dc.titleExploring Structure-Activity Relationships in Photodynamic Therapy Anticancer Agents Based on Ir(III)-COUPY Conjugates
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
738222.pdf
Mida:
3.71 MB
Format:
Adobe Portable Document Format